A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Rogier Gaiser et al.|Nature Medicine|2023Cited by 226
Nilotinib hampers the proliferation and function of CD8<sup>+</sup> T lymphocytes through inhibition of T cell receptor signallingJ. Chen, Michael Schmitt|Journal of Cellular and Molecular Medicine|2008Cited by 78
Effects of nilotinib on regulatory T cells: the dose mattersFei Fei, Michael Schmitt|Molecular Cancer|2010Cited by 29
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMASMichael Platten, Wolfgang Wick, Daniela Schilling et al.|Neuro-Oncology|2018Cited by 26
Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responsesMichael Schmitt, Jochen Greiner, Anita Schmitt et al.|Theranostics|2017Cited by 11